联系方式：400-650-8506
CNEN
产品名称 MHY 908
产品货号 Axon 2402 CAS [1393371-39-5] MF C17H14ClNO3SMW 347.82 Purity: 99% Soluble in 0.1N NaOH(aq) and DMSO Description Dual PPARα/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 more potently activated PPARα and PPARγ than fenofibrate and rosiglitazone, respectively, and enhanced the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance. References Certificates Categories Extra info M.H. Park et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8(11):e78815.   M.H. Park et al. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2014 Dec 14. [Epub ahead of print] Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Diabetes & Metabolism PPAR Tyrosinase NR1C; EC 1.14.18.1 Dual PPARα/γ agonist, and potent inhibitor of mushroom tyrosinase Chemical name 2-(4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy)-2-methylpropanoic acid Parent CAS No. [1393371-39-5] Order Size Unit Price Stock 5 mg €95.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

MHY 908

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2402

CAS [1393371-39-5]

MF C17H14ClNO3S
MW 347.82

  • Purity: 99%
  • Soluble in 0.1N NaOH(aq) and DMSO

MHY 908

Description

Dual PPARα/γ agonist, and potent inhibitor of melanogenesis by inhibition of mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 more potently activated PPARα and PPARγ than fenofibrate and rosiglitazone, respectively, and enhanced the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduced serum glucose, triglyceride, and insulin levels, however increased adiponectin levels without body weight gain. In addition, MHY 908 significantly improved hepatic steatosis by enhancing CPT-1 levels. Remarkably, MHY-908 reduced endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK) activation, and subsequently reduced insulin resistance.
产品资料